CTS Corporation (CTS) Company Overview

CTS Corporation is an NYSE-listed designer and manufacturer of engineered components that sense, connect, and move. It sells mainly to original equipment manufacturers. The portfolio includes position, current, and temperature sensors; pedals; actuators; switches; passive components; and piezoelectric ceramics, single crystals, and transducers. These custom solutions serve transportation, industrial, medical, and aerospace and defense applications. The official company overview identifies more than 20 locations in 12 countries.

How should readers map the product portfolio?

CTS reports one operating segment, so end markets and technologies provide the better map. Transportation uses pedals, position and current sensors, and actuators. Industrial applications include automation, metering, robotics, energy systems, and controls. Medical products use piezoelectric materials for ultrasound, minimally invasive procedures, and implanted devices. Aerospace and defense applications include sonar, underwater acoustics, communications, and unmanned-system sensing. The product catalog shows how CTS reuses core materials and engineering across verticals.

CTS earns product revenue by designing components into customer platforms and supplying them over each program’s production life. Engineers work with OEM teams on accuracy, safety, durability, size, materials, and cost. In FY2025, CTS sales engineers accounted for about 86% of sales; independent distributors and manufacturers’ representatives each accounted for about 7%. This direct technical channel improves customer knowledge and helps prototypes become multi-year production programs.

Why can custom engineering improve revenue quality?

Once a CTS part is validated inside a vehicle, ultrasound probe, industrial meter, or defense platform, switching can require redesign, testing, documentation, and requalification. These costs support retention, but OEMs still demand lower prices, quality, delivery, and upgrades. CTS must therefore keep winning on engineering and execution; standard products remain more exposed to distributor-led comparison.

The defining strategic shift is the move away from dependence on transportation toward industrial, medical, and aerospace and defense demand. In FY2025, transportation represented 43% of revenue, down from 49% in FY2024 and 55% in FY2023. Industrial contributed 26%, medical 16%, and aerospace and defense 15%. Together, the diversified markets reached 57% of sales, compared with 51% one year earlier. CTS’s FY2025 annual report states that diversified-market sales grew 16.3%, while transportation sales declined 6.6%.

Why does the diversified mix matter?

Diversification changes growth and profitability. Transportation provides scale, long programs, and opportunities in electrification, brake-by-wire, current sensing, and commercial vehicles, but volumes are cyclical and pricing pressure is substantial. Medical and defense products carry more specialized content. Better FY2025 mix helped gross profit rise 10.9%, faster than the 5.2% revenue increase.

The latest reported period is the quarter ended March 31, 2026. Net sales reached $139.2 million, up 10.7% year over year. Diversified-market sales increased 17.5%, transportation increased 2.9%, and foreign exchange added $2.9 million to reported sales. The Q1 2026 earnings release reported a book-to-bill ratio of 1.1, indicating orders exceeded revenue during the quarter, although this measure can change with amendments or cancellations.

Where did the earnings improvement come from?

Gross profit rose 18.1% to $55.0 million, and gross margin expanded from 37.0% to 39.5%. Management attributed the improvement to a richer diversified-market mix and operating efficiencies; foreign exchange added $0.7 million to gross profit. Operating earnings increased to $22.0 million, or 15.8% of sales, from $16.3 million, or 12.9%, in Q1 2025. Net earnings rose 28.7% to $17.2 million, and net margin reached 12.4%. SG&A was $26.0 million, or 18.7% of sales, while R&D was $6.6 million, or 4.8%.

CTS repeatedly migrated toward the component layer of new technology cycles. Its official history connects today’s portfolio to more than a century of adaptation.

1. 1896
   Chicago Telephone Supply was founded. The original competence was reliable electromechanical hardware for communications equipment.
2. 1922
   Radio components exceeded half of sales. CTS shifted from finished telephones toward components embedded in other manufacturers’ systems—the core logic of today’s OEM model.
3. 1960–62
   The company adopted the CTS name and listed on the NYSE. The identity changed from telephone supplier to diversified electronics manufacturer with access to public capital.
4. 1970s
   Automotive emissions controls opened the sensor market. Position sensing for throttle and exhaust systems became the foundation of a large transportation franchise.
5. 2007–12
   Alpha Ceramics, Tusonix, Valpey-Fisher, and D&R expanded materials, filters, timing, and automotive sensing. Acquisitions broadened the technology stack and customer base.
6. 2017–22
   Noliac, QTI, Sensor Scientific, Ferroperm, and TEWA strengthened piezoelectric and temperature sensing. These deals accelerated the move into medical and industrial applications.
7. 2024
   CTS acquired SyQwest for a $128.0 million purchase price. Sonar and acoustic sensing increased exposure to naval and defense platforms; SyQwest added $22.3 million of FY2025 sales.
8. 2026
   Pratik Trivedi became president and CEO; Kieran O’Sullivan moved to executive chair. The transition places a former operating chief in charge while preserving strategic continuity on the board.

Where are the most defensible resources?

CTS’s strongest resources are application engineering, proprietary material processes, qualification history, and customer-specific manufacturing know-how. CTS describes itself as the world’s largest fully integrated developer and manufacturer of PMN-PT and PIN-PMN-PT single crystals, used in premium medical ultrasound and underwater acoustics. Its single-crystal product page highlights in-house crystal growth, processing, and high-volume manufacturing.

Who competes with CTS?

Competition is fragmented by product line, and CTS says no rival spans its entire portfolio. Customers compare technology, price, quality, reliability, delivery, and service. Sensata Technologies and TE Connectivity are useful sensor-and-control comparisons; Amphenol overlaps in engineered connectivity; TDK, Murata, and ceramics specialists compete in advanced materials. The result is a comparison set, not one clean peer group.

CTS entered 2026 with conservative leverage and strong cash conversion. FY2025 operating cash flow was $102.1 million versus $98.2 million in FY2024. After $15.7 million of capital spending, calculated free cash flow was $86.4 million, a 16.0% margin. At March 31, 2026, cash of $90.9 million exceeded $62.5 million of long-term debt by $28.4 million. The current ratio was about 2.5 times, from $266.0 million of current assets and $105.4 million of current liabilities.

What does liquidity allow CTS to do?

CTS had a $300.0 million revolving facility maturing in November 2030, with $235.9 million available at March 31, 2026 after borrowings and letters of credit. It was covenant-compliant. This capacity supports acquisitions and working capital, while cash generation funds routine capex, dividends, and repurchases. Strategic flexibility is high, but acquisitions must justify purchase accounting and integration risk through technology, customer access, and margins.

Which balance-sheet line deserves caution?

Goodwill of $208.7 million and net intangibles of $148.6 million totaled $357.3 million at March 31, 2026, about 46% of assets. They reflect the acquisition strategy and could produce impairment charges if acquired businesses underperform. Future organic growth and cash flow should be compared with capital spent on SyQwest, Ferroperm, TEWA, Maglab, and earlier deals.

CTS has dispersed institutional ownership rather than founder or family control. The 2026 proxy statement listed five holders above 5%, led by BlackRock at 15.13% and Vanguard at 9.68%. Because source dates vary, these figures are the proxy’s official snapshot, not real-time positions.

How did leadership and incentives change in 2026?

Effective July 6, 2026, Pratik Trivedi became president and CEO, while Kieran O’Sullivan moved to executive chair and remained on the board. The June 2026 Form 8-K said the board expanded from eight to nine directors. Trivedi’s package includes a $675,000 base salary, a target annual bonus equal to 100% of salary, and performance- and service-based equity. The 2025 proxy incentive framework weighted adjusted EPS at 60%, sales at 30%, and controllable working capital at 10%; long-term awards emphasized sales growth and operating cash flow. O’Sullivan owned 1.36% at the proxy record date. The transition adds operating accountability while preserving strategic continuity.

Where are the strongest growth opportunities?

Management combines mid-single-digit organic growth with technology-focused acquisitions. Opportunities include automation, robotics, current measurement, energy efficiency, metering, medical ultrasound, minimally invasive therapies, electrification, brake-by-wire, and underwater systems. The April 2026 investor presentation showed about $90 million of last-twelve-month medical revenue, up 25% year over year, against an estimated $1.5 billion market. New piezo formulations and the eBrake platform, which combines redundant Hall-effect and inductive sensing, extend the pipeline.

What could interrupt the strategy?

CTS faces customer concentration, program timing, technology obsolescence, pricing, supply-chain inputs, tariffs, currency, acquisition integration, environmental liabilities, cybersecurity, and cyclical demand. Customer exposure is immediate: in Q1 2026, Cummins represented 10.4% of sales and Toyota 8.5%, versus Toyota at 11.9% in Q1 2025. A program loss or production cut can affect revenue before replacement volume arrives.

Which risk is most important for valuation?

The main valuation risk is failure to convert diversification into durable organic growth. A DCF should not assume premium terminal growth unless medical, industrial, and defense design wins continue after acquisition effects fade. Margin reversal is the second risk if transportation weakness, pricing, tariffs, or materials overwhelm mix gains. Capital allocation is the third: repurchases and acquisitions create value only when their returns exceed the alternatives and the cost of capital.

Which KPIs matter most in a DCF or comparable-company model?

CTS should be modeled as a specialized engineered-components company driven by end-market mix, design-win durability, margins, and reinvestment. Forecast transportation separately from diversified markets despite one-segment reporting. Transportation depends on platform volumes and pricing; diversified growth depends on medical, industrial, and defense bookings plus organic performance from acquired technologies.

What should students, researchers, and investors monitor next?

• Whether FY2026 sales remain within the $560 million to $580 million guidance range and adjusted diluted EPS reaches $2.35 to $2.45.
• Whether diversified-market growth remains faster than transportation after foreign-exchange and acquisition effects are separated.
• Whether gross margin stays near the Q1 2026 level rather than reverting toward the 38.4% FY2025 baseline.
• Whether medical revenue, defense bookings, and industrial orders convert into sustained organic growth and a book-to-bill ratio around or above 1.0.
• Whether free cash flow funds acquisitions, repurchases, and dividends without materially increasing leverage.
• Whether customer concentration, tariffs, material costs, or China-related transportation pressure reappear in revenue and margin bridges.